Yatharth Targets 5,000 Beds by 2029, Confident on FY27 Growth

Yatharth Hospital & Trauma Care Services Limited — Q4 FY26 Earnings Call (held May 26, 2026; FY ended Mar 31, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “exceptional and a transformative year”, “strong operational execution”, “remain confident”, and “early success… gives us confidence”.
• Forward-looking language is assertive: “expect… operational by April 2027”, “confident of achieving… 5,000 beds over the next three years”, “growth trajectory… potentially surpassing”.

2. Key Themes from Management Commentary

• Strong FY26 growth and profitability with operating leverage
• FY26 revenue INR 12,072m (+36% YoY); EBITDA INR 2,921m (+30% YoY); EBITDA margin 24.2%.
• Q4 EBITDA margin 23.4%; “adjusted” EBITDA margin 30.4% in Q4 and 28.5% for FY26 (explicitly attributing to ramp-up losses and mix).
• New facility ramp-up is progressing faster than expected
• New Delhi + Faridabad Sector 20 contributed ~11% of Q4 revenue and are delivering “healthy operating metrics”.
• Agra integration (250 beds) described as “profitable” with monthly revenue run rate ~INR 7 crore and “double-digit EBITDA margins”.
• Cluster-based expansion strategy in NCR
• Gurugram cluster seeded via acquisition of an under-construction super-speciality hospital (Sector 40, Central Gurugram).
• Bed capacity now >3,200 beds; target 5,000 beds in 3 years.
• Clinical excellence and specialty mix as the core value driver
• Emphasis on quaternary care, advanced technologies (e.g., Da Vinci robot in Agra; neurosurgical and GI milestones).
• Oncology and other super-specialities positioned as key ARPOB levers (e.g., Noida Extension oncology share cited as rising to ~30%).
• Payer mix optimization to support realizations and working capital
• Management reiterates intent to reduce government mix over time; new hospitals are positioned as cash/TPA-heavy.
• International patient growth as a realization lever
• Jewar airport partnership and international outreach framed as a structural tailwind (with specific ARPOB expectations for Gurugram).

3. Q&A Analysis

Theme A: Operational performance of newer hospitals (occupancy, ARPOB, ramp-up)

• Core questions
• How are Agra, Model Town (Delhi), Faridabad Sector 20, Jhansi, and Gurugram performing operationally?
• Why is Jhansi ARPOB lower—does it impact group?
• Management response
• Provided hospital-wise occupancy/census details (e.g., Model Town 32%, Faridabad Sector 20 52%, Agra 52%, Jhansi ~85%).
• Jhansi ARPOB lower than group average but “impact at a group level is not significant” due to “very less” revenue contribution.
• Notable/strong or evasive elements
• Strong: clear occupancy figures and explicit group-level impact minimization for Jhansi.
• Partial: limited discussion on why Jhansi ARPOB is structurally lower beyond “lower than group average”.

Theme B: Debt/interest cost and balance sheet trajectory

• Core questions
• Why did interest cost rise sequentially?
• What is debt/net debt outlook?
• Management response
• Interest cost increase attributed to loan taken to fund Agra.
• Debt stated as INR 230 crores, net debt INR 116 crores / net cash INR 115 crores (wording is slightly inconsistent but directionally “manageable”).
• Notable elements
• Partial: no detailed amortization schedule; relies on internal accruals and cash conversion.

Theme C: ARPOB guidance and drivers (including oncology share)

• Core questions
• Any levels for increasing ARPOB going forward?
• What explains ARPOB jump in Noida Extension/Greater Noida?
• Oncology share trajectory (e.g., Noida Extension oncology %).
• Management response
• Gurugram ARPOB expected >INR 50,000; group ARPOB growth “close to 10%” for upcoming years.
• Noida Extension/Greater Noida ARPOB jump attributed to OPD→IPD conversion and maturing super-specialities plus international patient share.
• Oncology share in Noida Extension cited as rising to ~30% (from ~19–20% earlier), driven by surgical oncology and bone marrow transplants; added oncology team.
• Notable elements
• Strong: specific oncology share and mechanistic explanation (OPD/IPD + international + super-speciality maturation).
• Potentially optimistic: “growth should be close to 10%” and Gurugram ARPOB >50k without quantified sensitivity.

Theme D: FY27 outlook: revenue growth, margins, breakeven timelines

• Core questions
• How should revenue/margins look in FY27 given ramp-up and new acquisitions?
• When will New Delhi and Faridabad hospitals breakeven?
• Any guidance on EBITDA margin range?
• Management response
• Margin guidance reiterated: consolidated EBITDA margin ~24%–25%, “no variation”.
• Expect FY27 revenue growth to surpass 36% YoY (explicitly stated).
• Breakeven: Faridabad Sector 20 ~10th–11th month; Delhi ~14–15 months; combined FY27 H2 EBITDA breakeven.
• Notable elements
• Unusually strong: “surpass this 36% YoY revenue growth” and “EBITDA margins should actually be better” while also saying margin guidance won’t vary—some tension in narrative.

Theme E: Working capital / debtor days

• Core questions
• Outlook for debtor days by end of FY27.
• Management response
• Debtor days: FY25 124, FY26 112; FY27 outlook 90–95 days.
• Notable elements
• Strong: quantitative target with clear historical improvement trend.

Theme F: Payer mix and government share reduction

• Core questions
• Government payer mix trend; impact of West Asia crisis on international patients.
• How much government business in new hospitals?
• Management response
• Government mix expected to fall: new hospitals government business not more than 10%–12% within two years; overall government business to reach ~25% in two years.
• International patients: acknowledged industry dip due to West Asia disruptions; expects “coming quarter… numbers will be much better” and cites African market focus.
• Notable elements
• Balanced: admits short-term dip risk but counters with diversification (Africa) and expected normalization.

Theme G: CGHS rate revision benefit and oncology drug pricing impact

• Core questions
• Quantify CGHS rate benefit and whether it impacts FY27.
• Any disruption due to chemotherapy drug pricing controls?
• Management response
• CGHS revised guidelines: “upside of around 5% in overall business” and “more than 3% of that has flown to EBITDA”.
• Clarified timing: full effect of 5% “will come in the next financial year by FY2027”.
• Oncology drugs: impact described as “marginal”; oncology is ~10% of revenue; pricing impact within that ~20%–30% of pricing for affected drugs; not stopped; mitigation via substitutes and other oncology streams.
• Notable elements
• Strong: timing clarification on CGHS benefit reduces risk of overcounting.
• Partial: “not huge impact” but no volume data provided.

Theme H: Brownfield expansion status and capex per bed

• Core questions
• Status/timeline for brownfield expansions (Greater Noida, Noida Extension).
• Cost per bed and energy price escalation risk.
• Management response
• Greater Noida brownfield: structural drawings finalized; construction started.
• Noida Extension: legal formalities completed; on track; brownfield timed to match occupancy ramp-up.
• Capex per bed for brownfield: ~INR 75 lakhs per bed; “no escalation” expected.
• Notable elements
• Strong: explicit capex/bed and escalation stance.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Bed capacity
• Total beds >3,200; target 5,000 beds over next 3 years.
• Gurugram facility
• Expected operational by April 2027.
• Expected ARPOB >INR 50,000.
• ARPOB growth
• “close to 10%” growth for upcoming years (qualitative but stated as a level).
• EBITDA margin
• Consolidated EBITDA margin guidance: ~24%–25% for FY27; “no variation”.
• Revenue growth
• FY27 revenue growth expected to surpass 36% YoY.
• Breakeven
• Faridabad Sector 20: ~10th–11th month.
• Delhi (Model Town): ~14–15 months.
• Combined: FY27 H2 EBITDA breakeven.
• Working capital
• Debtor days outlook FY27: 90–95 days.
• CGHS benefit timing
• Full effect of 5% overall revenue benefit expected in FY27 (timing clarification).

Implicit signals (qualitative)

• Management expects EBITDA margins to improve as ramp-up losses normalize, despite reiterating “no variation” in margin guidance.
• Confidence in sustaining growth trajectory and potentially surpassing prior YoY growth.
• Expansion funding confidence: “no plan to raise any fund” for 5,000-bed capacities; relies on cash conversion and internal accruals.

5. Standout Statements (directly revealing)

• Growth confidence
• “We remain confident of achieving our target of 5,000 beds over the next three years.”
• “We feel that in ’27, this we would surpass this 36% YoY revenue growth.”
• Margin stance
• “Our margin guidance has always been somewhere around 24% to 25%. And we have been delivering on that. And going forward also, we do not see any variation”
• Yet also: “EBITDA margins, next financial year EBITDA margins should actually be better.”
• Gurugram ARPOB
• “We expect ARPOB in Gurugram to be upwards of INR 50,000.”
• Working capital
• “outlook… around 90 to 95 days” debtor days for FY27.
• Jhansi impact minimization
• “even though Jhansi ARPOB is lower… the impact at a group level is not significant”
• CGHS benefit timing
• “complete effect of 5% was come only in the Q4 quarter of FY2026. For the complete effect of 5% will come in the next financial by FY2027.”
• International patient risk acknowledgement
• “we saw… a dip across the industry… But we believe that… coming quarter… numbers will be much better.”

6. Red Flags / Positive Signals

Red flags
– Narrative tension on margins: simultaneously says “no variation” in 24–25% guidance while also stating FY27 EBITDA margins “should actually be better.”
– Debt/net cash wording inconsistency: mentions debt INR 230 crores and net debt INR 116 crores / net cash INR 115 crores—could confuse readers on true net position.
– High confidence on revenue growth (“surpass 36%”) without quantified sensitivity to payer mix, occupancy, or international normalization.

Positive signals
– Clear operational metrics: hospital-wise occupancy and ARPOB provided in Q&A.
– Working capital target: debtor days improvement to 90–95 is specific and backed by historical trend (124 → 112).
– CGHS benefit timing clarified (reduces risk of double counting).
– Mitigation on oncology drug pricing: acknowledges impact but frames as limited and manageable.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q1 FY26 (Aug 2025): optimistic, focused on “stellar performance”, new hospital ramp-up; less emphasis on detailed working-capital targets.
• Q2 FY26 (Nov 2025): still optimistic; governance and income tax unfreezing highlighted; more operational detail (occupancy/ARPOB).
• Q3 FY26 (Feb 2026): strong confidence; “industry-leading performance”; continued emphasis on ramp-up and CGHS benefits.
• Q4 FY26 (May 2026): more assertive on forward growth (FY27 revenue “surpass 36%”) and bed targets; also more detailed on debtor days and capex per bed.
• Classification shift: More Optimistic (greater certainty and more aggressive FY27 growth language).

b. Tracking Past Commitments vs Outcomes

• Income tax issue resolution
• Prior (Q2 FY26): unfreezing provisional attached properties; expected resolution timeline.
• Current (Q4 FY26): “almost at its final leg of conclusion” and “no financial liability”; resolution expected before Quarter 2.
• Assessment: ✅ Progressed materially (unfreezing already happened; now near-final).
• EBITDA margin stability
• Prior (Q3 FY26): guidance blended EBITDA margin 24%–25%.
• Current: reiterates 24%–25% and claims FY27 should be better.
• Assessment: ✅ Consistent on guidance; ⏳ “better” claim depends on execution.
• Debtor days improvement
• Prior (Q3 FY26): hoped to close March 2027 with receivable days <110.
• Current: debtor days outlook FY27 90–95.
• Assessment: ⏳ More ambitious than prior expectation; not yet achieved but directionally consistent with improvement (112 in FY26).
• Brownfield timelines
• Prior (Q3 FY26): brownfield commissioning expected around 15 months (Greater Noida) and 17–18 months (Noida Extension) (as per earlier Q&A).
• Current: Greater Noida brownfield structural drawings finalized and construction started; Noida Extension on track with legal formalities completed.
• Assessment: ✅ On track / consistent narrative.

c. Narrative Shifts

• From “Jhansi as a growth/ROI story” to “Jhansi as immaterial to group”
• Earlier calls treated Jhansi as a meaningful contributor to occupancy growth and brand goodwill.
• Now, when ARPOB is questioned, management emphasizes group-level insignificance.
• International patient story becomes more operational
• Earlier: medical value travel initiatives and airport anticipation.
• Now: international patient share explicitly tied to ARPOB uplift and Gurugram expectations.

d. Consistency & Credibility Signals

• Credibility: Medium to High
• Strengths: repeated quantitative metrics (occupancy, ARPOB, debtor days), consistent margin guidance, and clearer timing on CGHS benefit.
• Weakness: some overconfidence (FY27 revenue “surpass 36%”) and occasional ambiguity in balance sheet net debt/net cash phrasing.

e. Evolution of Key Themes

• Demand / occupancy: stable-to-improving; newer hospitals show headroom (occupancy far below capacity) which supports future ramp-up.
• Margins: management increasingly frames margins as resilient due to operating leverage and mix; less discussion of downside scenarios.
• Expansion: shift from “announcing 3,000 beds” (earlier) to “>3,200 beds now” and “5,000 beds in 3 years” with more explicit capex/bed and acquisition vs greenfield split (70/30).
• Working capital: becomes more central in Q4 with a specific FY27 debtor-day target.

f. Additional Insights (cross-period intelligence)

• Risk diversification is becoming explicit:
• West Asia disruption acknowledged; management counters with Africa focus and expects normalization—this is a new, more explicit risk-management narrative vs earlier calls.
• Margin narrative is increasingly “execution-based” rather than “policy-based”:
• Earlier calls leaned more on CGHS rate revisions and government payer dynamics; current call leans more on occupancy ramp-up, specialty maturation, and international mix.